Emerging safety issues in alemtuzumab-treated MS patients
Mult Scler
.
2019 Aug;25(9):1206-1208.
doi: 10.1177/1352458519851219.
Authors
Joep Killestein
1
,
Bob van Oosten
1
Affiliation
1
Department of Neurology, Amsterdam UMC, Location VUmc, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
PMID:
31368417
PMCID:
PMC6681426
DOI:
10.1177/1352458519851219
No abstract available
Publication types
Comment
MeSH terms
Alemtuzumab
Antibodies, Monoclonal, Humanized
Humans
Incidence
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting*
Substances
Antibodies, Monoclonal, Humanized
Alemtuzumab